Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

Loading...
Thumbnail Image
Date
2026
Authors
Pascual-Lucas, María
Lacosta, Ana María
Montañés, María
Canudas, Jesús
Loscos, Jorge
Monleón, Inmaculada
Allué, José Antonio
Sarasa, Leticia
Fandos, Noelia
Romero, Judith
Other authors
Impact
Export
Share
Journal Title
Journal ISSN
Volume Title
Related resource
Citation
Journal or Serie
Alzheimer's and Dementia, 2026, vol. 22, núm. 8